Navigation Links
Monogram Announces a 6-to-1 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) today announced that its Board of Directors has approved a 6-to-1 reverse split of its common stock, as previously authorized and approved by the Company's stockholders at the September 19, 2007 annual meeting. The Company's common stock will begin trading on a post- split basis on November 4, 2008, under the temporary trading symbol "MGRMD" for approximately 20 trading days before reverting to "MGRM" on or about December 2, 2008.

As a result of the reverse stock split, every six shares of Monogram Biosciences common stock will be combined into one share of common stock. The reverse stock split affects all the Company's common stock outstanding immediately prior to the effective time of the reverse stock split as well as the number of shares of common stock available for issuance under the Company's equity incentive plans. In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible debt or upon the exercise of stock options or warrants. The Company will pay cash in lieu of fractional shares based on the average of the high and low trading prices of the common stock for the five trading days immediately preceding the effective date of the reverse stock split. The reverse stock split will reduce the number of shares of the Company's common stock outstanding from approximately 135 million to approximately 22.5 million. In addition, the number of authorized shares of common stock will be reduced from 200 million to 84 million shares.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at

Forward Looking Statements

Certain statements in this press release are forward-looking, including statements regarding the planned reverse split of our common stock. These forward-looking statements are subject to risks and uncertainties and other factors, including potential Nasdaq proceedings to delist our common stock, our ability to regain compliance with Nasdaq listing requirements, the and impact of the reverse split of the shares of our common stock, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Announces Conference Call
2. Monogram Receives NASDAQ Notification
3. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
4. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
5. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
6. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
7. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
11. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
Breaking Biology News(10 mins):